Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

AEterna, Zentaris Enter Another LHRH Product Deal With Solvay

Jan. 26, 2004

By Aaron Lorenzo

Genaera Gains $20M Through Direct Stock Equity Placement

Jan. 23, 2004

By Aaron Lorenzo

Genaera Gains $20M Through Direct Stock Equity Placement

Jan. 23, 2004

By Aaron Lorenzo

Cellular Genomics' Initial Close Of Series C Gathers Up $22.3M

Jan. 22, 2004

By Aaron Lorenzo

Cellular Genomics' Initial Close Of Series C Gathers Up $22.3M

Jan. 22, 2004

By Aaron Lorenzo

Genentech Beats 4Q Estimates, Files To Expand Nutropin Label

Jan. 16, 2004

By Aaron Lorenzo

Genentech Inc. released year-end and quarterly earnings that beat consensus estimates, simultaneously disclosing its application for an expanded indication of one of its growth hormone products. (BioWorld Today)

Genentech Beats 4Q Estimates, Files To Expand Nutropin Label

Jan. 16, 2004

By Aaron Lorenzo

Genentech Inc. released year-end and quarterly earnings that beat consensus estimates, simultaneously disclosing its application for an expanded indication of one of its growth hormone products. (BioWorld Today)

OxiGene Gets $22.3M, Plans Expansion Of CA4P Program

Jan. 15, 2004

By Aaron Lorenzo

OxiGene Gets $22.3M, Plans Expansion Of CA4P Program

Jan. 15, 2004

By Aaron Lorenzo

Curis Inks $170M Deal To License Hedgehog Technology To Wyeth

Jan. 14, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...